870823-12-4 Usage
Biological Activity
mk 0893 is an inhibitor of both glucagon receptor and igf-1r with ic50 values of 6.6nm and 6nm, respectively [1, 2].in a receptor binding assay using a membrane preparation from a cho cell line expressing the human gcgr, mk 0893 is shown to inhibit the bing between glucagon and the gcgr(ic50 value of 6.6 ± 3.5nm) and subsequently induce camp production(ic50 value of 15.7 ± 5.4nm). mk 0893 is proved to be a competitive, reversible gcgr antagonist, as evidenced by schild analysis in this cell line. and in an acute glucagon challenge model in hgcgr mice, mk 0893 is found to be active in blunting glucagon-induced glucose excursion. all these effects make mk 0893 be a potential oral treatment for type 2 diabetes. additionally, mk 0893 is also reported as a potent, selective, and orally bioavailable igf-1r inhibitor with robust in vivo efficacy in an igf-driven mouse xenograft model. [1, 2].
references
[1] yusheng xiong, jian guo, mari r. candelore, rui liang, corey miller, qing dallas-yang, guoqiang jiang, peggy e. mccann, sajjad a. qureshi, xinchun tong, shiyao sherrie xu, jackie shang, stella h. vincent, laurie m. tota, michael j. wright, xiaodong yang, bei b. zhang, james r. tata, and emma r. parmee. discovery of a novel glucagon receptor antagonist n-[(4-{(1s)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1h-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (mk-0893) for the treatment of type ii diabetes. journal of medicinal chemistry. 2012, 55: 6137-6148.[2] meizhong jin, andrew kleinberg, andy cooke, prafulla c. gokhale, kenneth foreman, hanqing dong, kam w. siu, mark a. bittner, kristen m. mulvihill, yan yao, darla landfair, matthew o’connor, gilda mak, jonathan a. pachter, robert wild, maryland rosenfeld-franklin, qunsheng ji, mark j. mulvihill. potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy. bioorganic & medicinal chemistry letters. 2011, 21: 1176–1180.
Check Digit Verification of cas no
The CAS Registry Mumber 870823-12-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,0,8,2 and 3 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 870823-12:
(8*8)+(7*7)+(6*0)+(5*8)+(4*2)+(3*3)+(2*1)+(1*2)=174
174 % 10 = 4
So 870823-12-4 is a valid CAS Registry Number.
InChI:InChI=1/C32H27Cl2N3O4/c1-19(20-3-5-21(6-4-20)32(40)35-12-11-31(38)39)37-30(18-29(36-37)25-14-26(33)17-27(34)15-25)24-8-7-23-16-28(41-2)10-9-22(23)13-24/h3-10,13-19H,11-12H2,1-2H3,(H,35,40)(H,38,39)/t19-/m0/s1
870823-12-4Relevant articles and documents
Discovery of a novel glucagon receptor antagonist N-[(4-{(1 S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1 H -pyrazol-1-yl]ethyl}phenyl) carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes
Xiong, Yusheng,Guo, Jian,Candelore, Mari R.,Liang, Rui,Miller, Corey,Dallas-Yang, Qing,Jiang, Guoqiang,McCann, Peggy E.,Qureshi, Sajjad A.,Tong, Xinchun,Xu, Shiyao Sherrie,Shang, Jackie,Vincent, Stella H.,Tota, Laurie M.,Wright, Michael J.,Yang, Xiaodong,Zhang, Bei B.,Tata, James R.,Parmee, Emma R.
, p. 6137 - 6148 (2012/09/07)
A potent, selective glucagon receptor antagonist 9m, N-[(4-{(1S)-1-[3-(3,5- dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl) carbonyl]-β-alanine, was discovered by optimization of a previously identified lead. Compound 9m is a reversible and competitive antagonist with high binding affinity (IC50 of 6.6 nM) and functional cAMP activity (IC50 of 15.7 nM). It is selective for glucagon receptor relative to other family B GPCRs, showing IC50 values of 1020 nM for GIPR, 9200 nM for PAC1, and >10000 nM for GLP-1R, VPAC1, and VPAC2. Compound 9m blunted glucagon-induced glucose elevation in hGCGR mice and rhesus monkeys. It also lowered ambient glucose levels in both acute and chronic mouse models: in hGCGR ob/ob mice it reduced glucose (AUC 0-6 h) by 32% and 39% at 3 and 10 mpk single doses, respectively. In hGCGR mice on a high fat diet, compound 9m at 3, and 10 mpk po in feed lowered blood glucose levels by 89% and 94% at day 10, respectively, relative to the difference between the vehicle control and lean hGCGR mice. On the basis of its favorable biological and DMPK properties, compound 9m (MK-0893) was selected for further preclinical and clinical evaluations.
Pyrazole derivatives, compositions containing such compounds and methods of use
-
Page/Page column 26, (2008/06/13)
Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
